Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

Figure 2

HM1.24-targeted therapy with mAbs and CTLs. Defucosylated AHM induces ADCC activity against MM cells including cancer stem cell-like cells (CSCs) in the presence of human effector cells such as NK cells. On the other hand, functional dendritic cells and HM1.24 peptide-specific CTLs can be induced from PBMCs or PBSC harvests, and these CTLs have the cytotoxic activity against MM cells. Len augments the activity of these cellular immunities.